Dashboard
Manage Tickers

EOLSEvolus, Inc.

Nasdaq evolus.com


$ 15.09 $ 0.38 (2.58 %)    

Monday, 09-Sep-2024 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 15.09
$ 15.09 x 100
-- x --
-- - --
$ 7.44 - $ 16.29
529,913
na
952.1M
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 03-07-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-08-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-02-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-03-2022 12-31-2021 10-K
12 11-02-2021 09-30-2021 10-Q
13 08-04-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 03-25-2021 12-31-2020 10-K
16 10-29-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-04-2019 09-30-2019 10-Q
21 08-12-2019 06-30-2019 10-Q
22 05-01-2019 03-31-2019 10-Q
23 03-20-2019 12-31-2018 10-K
24 11-05-2018 09-30-2018 10-Q
25 08-02-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-29-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-evolus
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 17:01:55

Cantor Fitzgerald analyst Louise Chen reiterates Evolus (NASDAQ:EOLS) with a Overweight.

hc-wainwright--co-reiterates-buy-on-evolus-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on Evol...
08/01/2024 12:32:55

HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $27 price target.

needham-reiterates-buy-on-evolus-maintains-22-price-target
Needham Reiterates Buy on Evolus, Maintain...
08/01/2024 09:36:19

Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.

evolus-q2-2024-adj-eps-004-beats-005-estimate-sales-66909m-beat-65784m-estimate
Evolus Q2 2024 Adj. EPS $(0.04) Beats $(0....
07/31/2024 21:53:29

Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 ...

evolus-raises-fy24-net-revenue-guidance-from-255m---265m-to--260m---270m-est-262495m
Evolus Raises FY24 Net Revenue Guidance Fr...
07/31/2024 21:31:53

The company continues to expect its adjusted gross profit margin for the full year 2024 to be between 68% and 71%. The compa...

evolus-expands-global-footprint-with-introduction-of-nuceiva-in-australia
Evolus Expands Global Footprint With Intro...
07/30/2024 12:14:13

Launching into this growth market1 as part of the company's geographic expansion strategyEvolus Australia established to dr...

evolus-announces-submission-of-premarket-approval-application-to-the-us-fda-for-first-two-evolysse-dermal-filler-products
Evolus Announces Submission Of Premarket A...
06/24/2024 12:09:54

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, to...

cantor-fitzgerald-reiterates-overweight-on-evolus
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 17:32:18

Cantor Fitzgerald analyst Louise Chen reiterates Evolus (NASDAQ:EOLS) with a Overweight.

evolus-expands-international-presence-with-launch-of-nuceiva-in-spain
Evolus Expands International Presence With...
06/12/2024 12:04:54

Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company's geographic expa...

hc-wainwright--co-reiterates-buy-on-evolus-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on Evol...
05/21/2024 10:38:11

HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $27 price target.

evolus-dermal-filler-evolysse-lift-meets-primary-endpoint-demonstrates-superiority-to-restylane-l-at-6-months-shows-statistically-significant-improvement-in-nasolabial-fold-severity-compared-to-restylane-l-at-all-timepoints-over-12-months
Evolus Dermal Filler Evolysse Lift Meets P...
05/20/2024 12:31:57

hc-wainwright--co-reiterates-buy-on-evolus-maintains-27-price-target
HC Wainwright & Co. Reiterates Buy on Evol...
05/08/2024 19:10:28

HC Wainwright & Co. analyst Douglas Tsao reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $27 price target.

needham-reiterates-buy-on-evolus-maintains-22-price-target
Needham Reiterates Buy on Evolus, Maintain...
05/08/2024 10:53:39

Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.

evolus-q1-2024-adj-eps-008-beats-010-estimate-sales-59333m-beat-57321m-estimate
Evolus Q1 2024 Adj EPS $(0.08) Beats $(0.1...
05/07/2024 20:39:44

Evolus (NASDAQ:EOLS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 20 ...

evolus-announces-publication-of-safety-and-duration-data-from-phase-2-study-for-extra-strength-40u-formulation-of-jeuveau
Evolus Announces Publication Of Safety and...
04/17/2024 20:13:03

The article published in Aesthetic Surgery Journal supports safety and duration of effect for temporary improvement in the appe...

needham-reiterates-buy-on-evolus-maintains-22-price-target
Needham Reiterates Buy on Evolus, Maintain...
04/10/2024 10:47:23

Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.

12-health-care-stocks-moving-in-thursdays-after-market-session
12 Health Care Stocks Moving In Thursday's...
03/21/2024 21:33:35

evolus-reports-pricing-of-50m-offering-of-common-stock
Evolus Reports Pricing Of $50M Offering Of...
03/11/2024 11:03:44

In addition, Evolus has granted the underwriters a 30-day option to purchase up to an additional 533,100 shares of common stock...

stifel-reiterates-buy-on-evolus-raises-price-target-to-25
Stifel Reiterates Buy on Evolus, Raises Pr...
03/08/2024 15:36:41

Stifel analyst Annabel Samimy reiterates Evolus (NASDAQ:EOLS) with a Buy and raises the price target from $23 to $25.

needham-reiterates-buy-on-evolus-maintains-22-price-target
Needham Reiterates Buy on Evolus, Maintain...
03/08/2024 12:08:30

Needham analyst Serge Belanger reiterates Evolus (NASDAQ:EOLS) with a Buy and maintains $22 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION